DCPH
Income statement / Annual
Last year (2023), Deciphera Pharmaceuticals, Inc.'s total revenue was $163.36 M,
an increase of 21.87% from the previous year.
In 2023, Deciphera Pharmaceuticals, Inc.'s net income was -$194.94 M.
See Deciphera Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$163.36 M |
$134.04 M |
$96.15 M |
$42.09 M |
$25.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.73 M
|
$8.77 M
|
$2.93 M
|
$225,000.00
|
$830,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$159.62 M
|
$125.27 M
|
$93.22 M
|
$41.86 M
|
$24.17 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.98
|
0.93
|
0.97
|
0.99
|
0.97
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$234.12 M
|
$187.82 M
|
$257.04 M
|
$198.97 M
|
$157.61 M
|
$82.89 M
|
$39.51 M
|
$20.16 M
|
$12.48 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$21.21 M
|
$11.42 M
|
$5.68 M
|
$5.14 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$136.46 M
|
$120.17 M
|
$136.25 M
|
$114.08 M
|
$68.12 M
|
$21.21 M
|
$11.42 M
|
$5.68 M
|
$5.14 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4,000.00
|
$0.00
|
| Operating Expenses |
$370.58 M
|
$307.99 M
|
$393.29 M
|
$313.05 M
|
$225.73 M
|
$104.10 M
|
$50.94 M
|
$25.84 M
|
$17.61 M
|
| Cost And Expenses |
$374.31 M
|
$316.76 M
|
$396.23 M
|
$313.28 M
|
$225.73 M
|
$104.10 M
|
$50.94 M
|
$25.84 M
|
$17.61 M
|
| Interest Income |
$16.45 M
|
$4.51 M
|
$113,000.00
|
$4.70 M
|
$8.54 M
|
$4.33 M
|
$746,000.00
|
$0.00
|
$3,000.00
|
| Interest Expense |
$0.00
|
$4.51 M
|
$0.00
|
$0.00
|
$67,000.00
|
$84,000.00
|
$95,000.00
|
$106,000.00
|
$2.21 M
|
| Depreciation & Amortization |
$2.10 M
|
$2.95 M
|
$3.01 M
|
$7.01 M
|
$8.54 M
|
$317,000.00
|
$150,000.00
|
$90,000.00
|
$73,000.00
|
| EBITDA |
-$208.86 M |
-$182.72 M |
-$300.08 M |
-$264.18 M |
-$192.19 M |
-$99.77 M |
-$50.04 M |
-$25.74 M |
-$17.53 M |
| EBITDA Ratio |
-1.28
|
-1.36
|
-3.12
|
-6.28
|
-7.69
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.29
|
-1.36
|
-3.12
|
-6.44
|
-8.03
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$16.45 M
|
$4.51 M
|
$113,000.00
|
$4.70 M
|
$8.47 M
|
$4.25 M
|
$651,000.00
|
-$102,000.00
|
-$2.21 M
|
| Income Before Tax |
-$194.51 M
|
-$178.21 M
|
-$299.96 M
|
-$266.49 M
|
-$192.26 M
|
-$99.85 M
|
-$50.28 M
|
-$25.94 M
|
-$19.82 M
|
| Income Before Tax Ratio |
-1.19
|
-1.33
|
-3.12
|
-6.33
|
-7.69
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$431,000.00
|
$722,000.00
|
-$3.13 M
|
$0.00
|
-$763,000.00
|
$4.33 M
|
$746,000.00
|
$110,000.00
|
$3,000.00
|
| Net Income |
-$194.94 M
|
-$178.93 M
|
-$296.84 M
|
-$266.49 M
|
-$191.49 M
|
-$99.85 M
|
-$50.28 M
|
-$25.94 M
|
-$19.82 M
|
| Net Income Ratio |
-1.19
|
-1.33
|
-3.09
|
-6.33
|
-7.66
|
0
|
0
|
0
|
0
|
| EPS |
-2.29 |
-2.37 |
-5.11 |
-4.78 |
-4.47 |
-2.82 |
-2.99 |
-1.24 |
-0.95 |
| EPS Diluted |
-2.29 |
-2.37 |
-5.11 |
-4.78 |
-4.47 |
-2.82 |
-2.99 |
-1.24 |
-0.95 |
| Weighted Average Shares Out |
$85.06 M
|
$75.50 M
|
$58.08 M
|
$55.78 M
|
$42.87 M
|
$35.39 M
|
$16.79 M
|
$20.90 M
|
$20.90 M
|
| Weighted Average Shares Out Diluted |
$85.06 M
|
$75.50 M
|
$58.08 M
|
$55.78 M
|
$42.87 M
|
$35.39 M
|
$16.79 M
|
$20.90 M
|
$20.90 M
|
| Link |
|
|
|
|
|
|
|
|
|
